RxDoctor Payments Data

Kevin Liu, MD

Family Medicine · Keller, TXNPI 1437167046

Payments from drug & device makers

$1,334in general payments, 2019–2025

Across 64 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$234
  • Inari Medical, Inc.$190
  • GSK$145
  • Idorsia Pharmaceuticals US Inc$75
  • Novo Nordisk$71
  • Abbott$71
  • plus $550 from 21 others

What the payments were for

  • Food & beverage$1,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,334 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$64,075
Medicare patients
114
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$59,593
OzempicSemaglutide31$41,220
FarxigaDapagliflozin Propanediol11$11,794
EliquisApixaban11$10,643
SymbicortBudesonide/Formoterol Fumarate12$3,759
Celecoxib28$1,926
Bupropion XlBupropion Hcl38$1,588
Levothyroxine Sodium126$1,552
Rosuvastatin Calcium92$1,184
Gabapentin68$1,180
SynthroidLevothyroxine Sodium17$1,156
Esomeprazole Magnesium23$1,106
Pantoprazole Sodium51$935
Duloxetine Hcl26$912
Trazodone Hcl77$830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$15$59,59353 claims
Novo NordiskOzempic$71$41,22031 claims
AstraZenecaFarxiga, Symbicort$30$15,55323 claims
PfizerEliquis$234$10,64311 claims
AbbVieSynthroid$19$1,15617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Keller

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →